Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Fradet

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Journal of Cellular Biochemistry. Supplement|January 1, 1992
Intermediate endpoint biomarkers for chemopreventionG P Hemstreet, J Y Rao, R E Hurst, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|October 1, 1984
Immunoanatomic dissection of the human urinary tract by monoclonal antibodiesC Cordon-Cardo, N H Bander, Y Fradet, et al.
The Journal of Urology|September 1, 1996
Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology GroupS L Goldenberg, L H Klotz, J Srigley, et al.
Urology|March 1, 1996
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasiaM M Elhilali, E W Ramsey, J Barkin, et al.
Cytometry|January 1, 1991
Precision of DNA flow cytometry in inter-institutional analysesL L Wheeless, J S Coon, C Cox, et al.
Urology|July 22, 1998
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study GroupF J Debruyne, R Murray, Y Fradet, et al.
Urology|July 1, 1996
Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsiesD G Bostwick, T M Wheeler, M Blute, et al.
British Journal of Cancer|November 22, 2012
Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counsellingE Xylinas, E K Cha, M Sun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 9, 2022
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-upA V Balar, D E Castellano, P Grivas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upY Fradet, J Bellmunt, D J Vaughn, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Journal of Cellular Biochemistry. Supplement|January 1, 1992
Intermediate endpoint biomarkers for chemopreventionG P Hemstreet, J Y Rao, R E Hurst, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|October 1, 1984
Immunoanatomic dissection of the human urinary tract by monoclonal antibodiesC Cordon-Cardo, N H Bander, Y Fradet, et al.
The Journal of Urology|September 1, 1996
Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology GroupS L Goldenberg, L H Klotz, J Srigley, et al.
Urology|March 1, 1996
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasiaM M Elhilali, E W Ramsey, J Barkin, et al.
Cytometry|January 1, 1991
Precision of DNA flow cytometry in inter-institutional analysesL L Wheeless, J S Coon, C Cox, et al.
Urology|July 22, 1998
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study GroupF J Debruyne, R Murray, Y Fradet, et al.
Urology|July 1, 1996
Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsiesD G Bostwick, T M Wheeler, M Blute, et al.
British Journal of Cancer|November 22, 2012
Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counsellingE Xylinas, E K Cha, M Sun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 9, 2022
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-upA V Balar, D E Castellano, P Grivas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upY Fradet, J Bellmunt, D J Vaughn, et al.
Pageof 11